Alunbrig Unión Europea - español - EMA (European Medicines Agency)

alunbrig

takeda pharma a/s - brigatinib - carcinoma, pulmón no microcítico - agentes antineoplásicos - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

ALUNBRIG 90mg TABLETA RECUBIERTA Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

alunbrig 90mg tableta recubierta

takeda s.r.l. - tableta recubierta - por tableta; brigatinib 90.000000 mg; - brigatinib

ALUNBRIG 30mg TABLETA RECUBIERTA Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

alunbrig 30mg tableta recubierta

takeda s.r.l. - tableta recubierta - por tableta; brigatinib 30.000000 mg; - brigatinib

ALUNBRIG 180mg TABLETA RECUBIERTA Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

alunbrig 180mg tableta recubierta

takeda s.r.l. - tableta recubierta - por tableta; brigatinib 180.000000 mg; - brigatinib